Literature DB >> 7774062

Autoantibody response to the Ro/La particle may predict outcome in neonatal lupus erythematosus.

E D Silverman1, J Buyon, R M Laxer, R Hamilton, P Bini, J L Chu, K B Elkon.   

Abstract

This study was undertaken to determine the role of antibodies against both recombinant Ro (r-Ro) and La (r-La) proteins and polypeptides derived from the recombinant La protein in predicting fetal and neonatal outcome in children at risk to develop neonatal lupus erythematosus (NLE). All sera were obtained in the perinatal period and quantitative ELISA assays were used. We collected 41 maternal sera within 2 months of delivery of a child with NLE (21 with congenital heart disease block (CHB) and 20 with dermatologic NLE) and 19 sera from anti-Ro and/or anti-La antibody-positive mothers with systemic lupus erythematosus (SLE) who delivered a child without NLE. All sera were tested for anti-r-La and anti-r-Ro antibodies by ELISA, and most sera were tested for antibodies directed against La polypeptides by immunoblot. We found significantly higher anti-r-La antibody levels in the sera from mothers of children with NLE compared with sera from mothers of unaffected children (0.67 +/- 0.43 versus 0.14 +/- 0.30; P < 0.0001). There was a statistically significant difference in the mean anti-r-La levels between the sera of mothers of children with CHB compared with dermatologic NLE (0.51 +/- 0.45 versus 0.83 +/- 0.37 respectively; P = 0.0091). When we examined antibodies directed against the recombinant 52-kD Ro protein, there was a statistically significant elevation of titres in the sera of mothers of NLE children (0.77 +/- 0.35) compared with non-NLE mothers (0.29 +/- 0.39; P < 0.0001). There was no difference in the r-Ro levels between mothers of children with dermatologic NLE compared with CHB (0.82 +/- 0.37 versus 0.71 +/- 0.74; P = 0.32). When we examined polypeptides derived from the recombinant La protein, the mean number of polypeptides recognized by sera from mothers of children with NLE was significantly higher than the mean number of polypeptides recognized by sera from mothers of unaffected children (5.1 +/- 0.54 versus 2.3 +/- 0.54 respectively; P < 0.001). More importantly, when we examined the individual polypeptides, we found that only sera from mothers of children with NLE and not from mothers of unaffected children recognized a polypeptide designated DD (30% versus 0%, respectively). These studies indicate that the autoantibody response to the Ro/La particle can differentiate sera from mothers of children with NLE and sera from mothers of unaffected children. Furthermore, there was a difference in the anti-La autoantibody response between mothers of children with CHB and dermatologic NLE.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7774062      PMCID: PMC1534456          DOI: 10.1111/j.1365-2249.1995.tb03729.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  28 in total

1.  IgG antibodies from patients with primary Sjögren's syndrome and systemic lupus erythematosus recognize different epitopes in 60-kD SSA/Ro protein.

Authors:  S Barakat; O Meyer; F Torterotot; P Youinou; J P Briand; M F Kahn; S Muller
Journal:  Clin Exp Immunol       Date:  1992-07       Impact factor: 4.330

2.  Congenital heart block immunogenetics. Evidence of an additional role of HLA class III antigens and independence of Ro autoantibodies.

Authors:  A Arnaiz-Villena; J J Vazquez-Rodriguez; J L Vicario; P Lavilla; D Pascual; F Moreno; J Martinez-Laso
Journal:  Arthritis Rheum       Date:  1989-11

3.  The genetic basis of Ro and La antibody formation in systemic lupus erythematosus. Results of a multicenter study. The SLE Study Group.

Authors:  K Hartung; H Ehrfeld; H J Lakomek; R Coldewey; B Lang; F Krapf; R Müller; D Schendel; H Deicher; H P Seelig
Journal:  Rheumatol Int       Date:  1992       Impact factor: 2.631

Review 4.  Neonatal lupus erythematosus. A clinical, serological and immunogenetic study with review of the literature.

Authors:  R M Watson; A T Lane; N K Barnett; W B Bias; F C Arnett; T T Provost
Journal:  Medicine (Baltimore)       Date:  1984-11       Impact factor: 1.889

5.  Importance of the immune response to the Ro/La particle in the development of congenital heart block and neonatal lupus erythematosus.

Authors:  E Silverman; M Mamula; J A Hardin; R Laxer
Journal:  J Rheumatol       Date:  1991-01       Impact factor: 4.666

6.  Identification of mothers at risk for congenital heart block and other neonatal lupus syndromes in their children. Comparison of enzyme-linked immunosorbent assay and immunoblot for measurement of anti-SS-A/Ro and anti-SS-B/La antibodies.

Authors:  J P Buyon; R J Winchester; S G Slade; F Arnett; J Copel; D Friedman; M D Lockshin
Journal:  Arthritis Rheum       Date:  1993-09

7.  Definition of a discontinuous immunodominant epitope at the NH2 terminus of the La/SS-B ribonucleoprotein autoantigen.

Authors:  L J McNeilage; K Umapathysivam; E Macmillan; A Guidolin; S Whittingham; T Gordon
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

8.  Acquired congenital heart block. Pattern of maternal antibody response to biochemically defined antigens of the SSA/Ro-SSB/La system in neonatal lupus.

Authors:  J P Buyon; E Ben-Chetrit; S Karp; R A Roubey; L Pompeo; W H Reeves; E M Tan; R Winchester
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

9.  A case-control study of congenital heart block: association with maternal antibodies to Ro(SS-A) and La(SS-B).

Authors:  M McCredie; J Celermajer; G Sholler; D Kelly; T Chivers; Y Wang; L Schrieber
Journal:  Br J Rheumatol       Date:  1990-02

10.  U1RNP antibody-positive neonatal lupus. A report of two cases with immunogenetic studies.

Authors:  E M Dugan; W W Tunnessen; P J Honig; R M Watson
Journal:  Arch Dermatol       Date:  1992-11
View more
  7 in total

Review 1.  The clinical spectrum of autoimmune congenital heart block.

Authors:  Pilar Brito-Zerón; Peter M Izmirly; Manuel Ramos-Casals; Jill P Buyon; Munther A Khamashta
Journal:  Nat Rev Rheumatol       Date:  2015-03-24       Impact factor: 20.543

2.  Antibodies to amino acid 200-239 (p200) of Ro52 as serological markers for the risk of developing congenital heart block.

Authors:  L Strandberg; O Winqvist; S-E Sonesson; S Mohseni; S Salomonsson; K Bremme; J P Buyon; H Julkunen; M Wahren-Herlenius
Journal:  Clin Exp Immunol       Date:  2008-08-22       Impact factor: 4.330

Review 3.  Congenital heart block: evidence for a pathogenic role of maternal autoantibodies.

Authors:  Aurélie Ambrosi; Marie Wahren-Herlenius
Journal:  Arthritis Res Ther       Date:  2012-04-26       Impact factor: 5.156

Review 4.  Detection of autoantibodies in a point-of-care rheumatology setting.

Authors:  Konstantin N Konstantinov; Antonios Tzamaloukas; Robert L Rubin
Journal:  Auto Immun Highlights       Date:  2013-05-18

5.  Identification of a unique anti-Ro60 subset with restricted serological and molecular profiles.

Authors:  A Y S Lee; D Beroukas; L Brown; C Lucchesi; A Kaur; L Gyedu; N Hughes; Y H Ng; O Saran; T P Gordon; J J Wang
Journal:  Clin Exp Immunol       Date:  2020-09-17       Impact factor: 4.330

6.  Congenital heart block maternal sera autoantibodies target an extracellular epitope on the α1G T-type calcium channel in human fetal hearts.

Authors:  Linn S Strandberg; Xuezhi Cui; Arianna Rath; Jie Liu; Earl D Silverman; Xiaoru Liu; Vinayakumar Siragam; Cameron Ackerley; Brenda Bin Su; Jane Yuqing Yan; Marco Capecchi; Luca Biavati; Alice Accorroni; William Yuen; Filippo Quattrone; Kalvin Lung; Edgar T Jaeggi; Peter H Backx; Charles M Deber; Robert M Hamilton
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

7.  Neonatal Lupus erythematosus Following Rheumatoid Arthritis: Case Report and Literature Review.

Authors:  Raheleh Assari; Vahid Ziaee; Mohammad-Hassan Moradinejad; Arash Mirmohammadsadeghi
Journal:  Iran J Pediatr       Date:  2014-05-16       Impact factor: 0.364

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.